Biogen Inc.

NASDAQ Global Select
Back to all articles
Very Bullish +80

Biogen to acquire Apellis in $5.6bn deal

🧬 Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion.

💊 The deal includes Empaveli and Syfovre, two approved medicines adding immediate revenue.

💰 Empaveli and Syfovre combined reached $689 million in net sales in 2025.

📈 Revenue is expected to grow significantly over the next two years following acquisition.

👥 Empaveli treats rare immune-mediated kidney diseases, while Syfovre treats geographic atrophy from age-related macular degeneration.

🔬 The acquisition will support Biogen's nephrology franchise with felzartamab trials using Apellis' US infrastructure.

💼 CEO Cedric Francois stated the transaction will accelerate impact and reach more patients.

🏢 Biogen's CEO Christopher Viehbacher highlighted expanded portfolio growth in immunology and rare diseases.

📅 The deal is expected to close in the second quarter of 2026.

⚖️ Syfovre is approved for immune-mediated retinal disease, complementing Biogen's existing pipeline.

🎓 Apellis' talent and field capabilities will strengthen Biogen's operational foundation.

🏥 Felzartamab is currently in phase 3 trials for three kidney diseases.

Bullish Signals
  • Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6bn, enhancing its growth portfolio in immunology and rare disease.
  • The deal includes two commercialized medicines, Empaveli and Syfovre, which added combined net sales of $689m in 2025 and are expected to increase over the next two years.
  • Apellis' established US sales infrastructure will accelerate Biogen's commercial readiness for felzartamab, a phase 3 treatment for three kidney diseases.
  • The addition of Apellis bolsters near-and long-term growth potential with two FDA-approved, best-in-class medicines that complement Biogen's existing portfolio.
Risk Factors
  • Biogen is undertaking a $5.6bn acquisition of Apellis, representing a significant cash outflow that could strain liquidity or dilute shareholders.
  • The acquired company's key medicines Empaveli and Syfovre are expected to increase sales only over the next two years after reaching $689m in 2025, with no immediate revenue impact.
  • The acquisition relies on Apellis' established US sales infrastructure to accelerate Biogen's internal assets, creating integration risk if synergies fail to materialize.
  • Biogen's strategy is heavily concentrated in immunology and rare disease segments, increasing exposure to regulatory hurdles or market shifts specific to these niches.
Full Analysis
Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion in a transaction designed to expand its portfolio within the immunology and rare disease sectors. The deal brings two commercially available, differentiated medicines, Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan injection), which are expected to contribute immediate sales revenue and bolster both short- and long-term growth profiles. In 2025, these two products combined generated $689 million in net sales, a figure that is projected to increase over the subsequent two years following the acquisition. Empaveli was approved by the US FDA for the treatment of rare immune-mediated kidney diseases and paroxysmal nocturnal hemoglobinuria (PNH), while Syfovre is indicated for geographic atrophy secondary to age-related macular degeneration, an immune-mediated retinal condition. Beyond existing products, Apellis brings established US sales infrastructure that Biogen believes will accelerate commercial readiness for felzartamab, a treatment for three kidney diseases currently in phase 3 trials. This integration aims to strengthen Biogen's nephrology franchise and deepen its capabilities in serving patients with immune-mediated retinal disease. The acquisition is anticipated to close in the second quarter of 2026. Cedric Francois, co-founder and CEO of Apellis, stated that Biogen's extensive experience in immunology and rare diseases would accelerate the transaction's impact and enable reaching more patients. Christopher Viehbacher, Biogen's President and CEO, highlighted that adding Apellis expands their growth portfolio with two best-in-class medicines that complement existing offerings, while leveraging combined capabilities to maximize potential and further strengthen the company with Apellis' talent and field expertise.